Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Onco... (-positive breast cancer patients w...)

HOME >> MEDICINE >> TECHNOLOGY

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)

Date:12/17/2007

-positive

breast cancer patients with positive nodes. Researchers analyzed tumor

samples from patients in the SWOG/Breast Cancer Intergroup of North

America trial that evaluated postmenopausal patients with node

positive, hormone receptor-positive breast cancer who were treated with

chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil,

followed by tamoxifen) vs. tamoxifen alone. Chemotherapy did not

appear to benefit those with low Oncotype DX Recurrence Score results,

despite the presence of positive nodes. Conversely, a large benefit was

observed with the addition of chemotherapy in patients with high

Oncotype DX Recurrence Score results. These results join a suite of

studies that consistently demonstrate the value of the Oncotype DX

Recurrence Score result for individualized treatment planning, and show

that Oncotype DX may be clinically useful in some patients with hormone

receptor positive, node-positive breast cancer.

Oncotype DX Changes Treatment Decisions

Three studies assessing the impact of Oncotype DX on treatment decisions concluded that use of the test resulted in less recommendation for and use of chemotherapy. Collectively, these studies demonstrate the actionable nature of Oncotype DX in its ability to help reduce unnecessary use of chemotherapy, lowering both adverse effects and cost for these patients, while increasing patient confidence in their treatment selection.

* A prospective, multi-institutional study presented Thursday, December

13 by Loyola University Chicago Stritch School of Medicine evaluated 89

patients to determine the psychological impact of Oncotype DX

Recurrence Score results on patients' treatment decision-making and

anxiety. Use of Oncotype DX changed both physician and patient

decisions on adjuvant therapy select
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease

Post Your Comments:

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Onco...(-positive breast cancer patients w...),Health